^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLDN6-CAR-NK cell therapy

    i
    Other names: CLDN6-CAR-NK cell therapy, Claudin6 targeting CAR-NK cells
    Associations

    News

    Trials
    Company:
    Second Affiliated Hospital of Guangzhou Medical University
    Drug class:
    NK cell stimulant, CLDN6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. (PubMed, Int J Biol Sci)
    More importantly, CAR-NK cells combined with immune checkpoint inhibitors, anti-PD-L1, could synergistically enhance the antitumor efficacy of CLDN6-targeted CAR-NK cells. These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CLDN6 (Claudin 6) • NKG2D (killer cell lectin like receptor K1)
    |
    CLDN6 expression • CLDN6 positive
    |
    CLDN6-CAR-NK cell therapy
    over2years
    CLDN6-CAR-NK Cell Therapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Second Affiliated Hospital of Guangzhou Medical University
    New P1/2 trial
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression • CLDN6 positive
    |
    CLDN6-CAR-NK cell therapy